N

NextCure
D

NXTC

6.54000
USD
0.07
(1.08%)
مغلق
حجم التداول
2,019
الربح لكل سهم
-21
العائد الربحي
-
P/E
-0
حجم السوق
17,501,759
أصول ذات صلة الأخبار المقالات

العنوان: NextCure Inc

القطاع: Healthcare
الصناعة: Biotechnology
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.